nodes	percent_of_prediction	percent_of_DWPC	metapath
Ruxolitinib—ROCK1—Irinotecan—Topotecan—cervical cancer	0.0133	0.779	CbGdCrCtD
Ruxolitinib—Myelosuppression—Topotecan—cervical cancer	0.0106	0.161	CcSEcCtD
Ruxolitinib—PRKG2—renal system—cervical cancer	0.00526	0.0117	CbGeAlD
Ruxolitinib—Bone pain—Topotecan—cervical cancer	0.00518	0.0789	CcSEcCtD
Ruxolitinib—PLK1—uterine cervix—cervical cancer	0.00504	0.0112	CbGeAlD
Ruxolitinib—PLK1—mammalian vulva—cervical cancer	0.00441	0.00979	CbGeAlD
Ruxolitinib—PLK1—uterus—cervical cancer	0.0042	0.00932	CbGeAlD
Ruxolitinib—PLK3—decidua—cervical cancer	0.00401	0.00889	CbGeAlD
Ruxolitinib—CAMK1—uterine cervix—cervical cancer	0.00394	0.00873	CbGeAlD
Ruxolitinib—PRKCE—female reproductive system—cervical cancer	0.00393	0.00872	CbGeAlD
Ruxolitinib—PLK3—endometrium—cervical cancer	0.0038	0.00844	CbGeAlD
Ruxolitinib—PLK1—female reproductive system—cervical cancer	0.00378	0.00838	CbGeAlD
Ruxolitinib—RPS6KA6—female reproductive system—cervical cancer	0.00378	0.00838	CbGeAlD
Ruxolitinib—PLK1—Irinotecan—Topotecan—cervical cancer	0.00377	0.221	CbGdCrCtD
Ruxolitinib—CAMK1—decidua—cervical cancer	0.00375	0.00832	CbGeAlD
Ruxolitinib—PLK3—mammalian vulva—cervical cancer	0.00368	0.00817	CbGeAlD
Ruxolitinib—CAMK1—endometrium—cervical cancer	0.00356	0.0079	CbGeAlD
Ruxolitinib—CAMK1—mammalian vulva—cervical cancer	0.00344	0.00764	CbGeAlD
Ruxolitinib—JAK1—epithelium—cervical cancer	0.00326	0.00722	CbGeAlD
Ruxolitinib—DCLK3—vagina—cervical cancer	0.00324	0.00719	CbGeAlD
Ruxolitinib—JAK1—uterine cervix—cervical cancer	0.00323	0.00716	CbGeAlD
Ruxolitinib—DCLK1—uterine cervix—cervical cancer	0.00323	0.00716	CbGeAlD
Ruxolitinib—Alanine aminotransferase increased—Topotecan—cervical cancer	0.00318	0.0484	CcSEcCtD
Ruxolitinib—PLK3—female reproductive system—cervical cancer	0.00315	0.00699	CbGeAlD
Ruxolitinib—DAPK2—uterine cervix—cervical cancer	0.00308	0.00683	CbGeAlD
Ruxolitinib—JAK1—decidua—cervical cancer	0.00308	0.00682	CbGeAlD
Ruxolitinib—LTK—female reproductive system—cervical cancer	0.00304	0.00676	CbGeAlD
Ruxolitinib—JAK1—renal system—cervical cancer	0.00302	0.0067	CbGeAlD
Ruxolitinib—Pancytopenia—Topotecan—cervical cancer	0.00296	0.045	CcSEcCtD
Ruxolitinib—CAMK1—female reproductive system—cervical cancer	0.00295	0.00654	CbGeAlD
Ruxolitinib—JAK1—endometrium—cervical cancer	0.00292	0.00648	CbGeAlD
Ruxolitinib—Neutropenia—Topotecan—cervical cancer	0.00291	0.0443	CcSEcCtD
Ruxolitinib—PLK3—female gonad—cervical cancer	0.00287	0.00636	CbGeAlD
Ruxolitinib—CLK2—uterine cervix—cervical cancer	0.00287	0.00636	CbGeAlD
Ruxolitinib—MARK2—female reproductive system—cervical cancer	0.00286	0.00635	CbGeAlD
Ruxolitinib—PLK3—vagina—cervical cancer	0.00285	0.00633	CbGeAlD
Ruxolitinib—Weight increased—Topotecan—cervical cancer	0.00284	0.0432	CcSEcCtD
Ruxolitinib—JAK1—mammalian vulva—cervical cancer	0.00282	0.00627	CbGeAlD
Ruxolitinib—DCLK1—mammalian vulva—cervical cancer	0.00282	0.00627	CbGeAlD
Ruxolitinib—HIPK2—renal system—cervical cancer	0.00282	0.00626	CbGeAlD
Ruxolitinib—ROCK1—epithelium—cervical cancer	0.0028	0.00622	CbGeAlD
Ruxolitinib—DAPK2—endometrium—cervical cancer	0.00279	0.00618	CbGeAlD
Ruxolitinib—Infestation NOS—Topotecan—cervical cancer	0.00278	0.0423	CcSEcCtD
Ruxolitinib—Infestation—Topotecan—cervical cancer	0.00278	0.0423	CcSEcCtD
Ruxolitinib—DAPK3—decidua—cervical cancer	0.00276	0.00612	CbGeAlD
Ruxolitinib—CAMK1D—mammalian vulva—cervical cancer	0.00276	0.00612	CbGeAlD
Ruxolitinib—CLK2—decidua—cervical cancer	0.00273	0.00606	CbGeAlD
Ruxolitinib—DAPK3—renal system—cervical cancer	0.00271	0.00601	CbGeAlD
Ruxolitinib—DAPK2—mammalian vulva—cervical cancer	0.00269	0.00598	CbGeAlD
Ruxolitinib—JAK1—uterus—cervical cancer	0.00269	0.00597	CbGeAlD
Ruxolitinib—DCLK1—uterus—cervical cancer	0.00269	0.00597	CbGeAlD
Ruxolitinib—CLK2—renal system—cervical cancer	0.00268	0.00595	CbGeAlD
Ruxolitinib—CAMK1—female gonad—cervical cancer	0.00268	0.00595	CbGeAlD
Ruxolitinib—CAMK1—vagina—cervical cancer	0.00267	0.00592	CbGeAlD
Ruxolitinib—Hepatobiliary disease—Topotecan—cervical cancer	0.00263	0.04	CcSEcCtD
Ruxolitinib—Epistaxis—Topotecan—cervical cancer	0.00262	0.0399	CcSEcCtD
Ruxolitinib—DAPK3—endometrium—cervical cancer	0.00262	0.00581	CbGeAlD
Ruxolitinib—ROCK1—renal system—cervical cancer	0.0026	0.00577	CbGeAlD
Ruxolitinib—CLK2—endometrium—cervical cancer	0.00259	0.00576	CbGeAlD
Ruxolitinib—DYRK1A—decidua—cervical cancer	0.00258	0.00573	CbGeAlD
Ruxolitinib—NUAK2—uterine cervix—cervical cancer	0.00258	0.00573	CbGeAlD
Ruxolitinib—BMPR2—decidua—cervical cancer	0.00257	0.00571	CbGeAlD
Ruxolitinib—DYRK1A—renal system—cervical cancer	0.00254	0.00563	CbGeAlD
Ruxolitinib—DAPK3—mammalian vulva—cervical cancer	0.00253	0.00562	CbGeAlD
Ruxolitinib—BMPR2—renal system—cervical cancer	0.00253	0.00561	CbGeAlD
Ruxolitinib—CLK2—mammalian vulva—cervical cancer	0.00251	0.00557	CbGeAlD
Ruxolitinib—Haemoglobin—Topotecan—cervical cancer	0.00251	0.0382	CcSEcCtD
Ruxolitinib—Haemorrhage—Topotecan—cervical cancer	0.00249	0.038	CcSEcCtD
Ruxolitinib—NUAK2—decidua—cervical cancer	0.00246	0.00546	CbGeAlD
Ruxolitinib—JAK3—female reproductive system—cervical cancer	0.00243	0.0054	CbGeAlD
Ruxolitinib—JAK1—female reproductive system—cervical cancer	0.00242	0.00537	CbGeAlD
Ruxolitinib—CAMK2G—uterine cervix—cervical cancer	0.00242	0.00536	CbGeAlD
Ruxolitinib—BMP2K—uterine cervix—cervical cancer	0.00242	0.00536	CbGeAlD
Ruxolitinib—DAPK3—uterus—cervical cancer	0.00241	0.00535	CbGeAlD
Ruxolitinib—TAOK2—female gonad—cervical cancer	0.00241	0.00535	CbGeAlD
Ruxolitinib—PLK4—female reproductive system—cervical cancer	0.0024	0.00533	CbGeAlD
Ruxolitinib—TAOK2—vagina—cervical cancer	0.0024	0.00531	CbGeAlD
Ruxolitinib—LRRK2—uterine cervix—cervical cancer	0.00239	0.00531	CbGeAlD
Ruxolitinib—PHKG2—female reproductive system—cervical cancer	0.00235	0.00521	CbGeAlD
Ruxolitinib—NUAK2—endometrium—cervical cancer	0.00233	0.00518	CbGeAlD
Ruxolitinib—BMP2K—decidua—cervical cancer	0.0023	0.00511	CbGeAlD
Ruxolitinib—PRKCE—lymph node—cervical cancer	0.0023	0.0051	CbGeAlD
Ruxolitinib—LRRK2—decidua—cervical cancer	0.00228	0.00506	CbGeAlD
Ruxolitinib—STK16—female reproductive system—cervical cancer	0.00227	0.00504	CbGeAlD
Ruxolitinib—HIPK2—female reproductive system—cervical cancer	0.00226	0.00501	CbGeAlD
Ruxolitinib—NUAK2—mammalian vulva—cervical cancer	0.00226	0.00501	CbGeAlD
Ruxolitinib—BMPR2—uterus—cervical cancer	0.00225	0.00499	CbGeAlD
Ruxolitinib—LRRK2—renal system—cervical cancer	0.00224	0.00497	CbGeAlD
Ruxolitinib—JAK3—female gonad—cervical cancer	0.00221	0.00491	CbGeAlD
Ruxolitinib—MAP3K19—female reproductive system—cervical cancer	0.00221	0.00491	CbGeAlD
Ruxolitinib—RPS6KA6—lymph node—cervical cancer	0.00221	0.0049	CbGeAlD
Ruxolitinib—PLK1—lymph node—cervical cancer	0.00221	0.0049	CbGeAlD
Ruxolitinib—JAK1—female gonad—cervical cancer	0.0022	0.00488	CbGeAlD
Ruxolitinib—MAP3K2—uterine cervix—cervical cancer	0.00219	0.00487	CbGeAlD
Ruxolitinib—JAK1—vagina—cervical cancer	0.00219	0.00485	CbGeAlD
Ruxolitinib—DCLK1—vagina—cervical cancer	0.00219	0.00485	CbGeAlD
Ruxolitinib—CAMK2G—endometrium—cervical cancer	0.00219	0.00485	CbGeAlD
Ruxolitinib—BMP2K—endometrium—cervical cancer	0.00219	0.00485	CbGeAlD
Ruxolitinib—MAP3K7—uterine cervix—cervical cancer	0.00217	0.00482	CbGeAlD
Ruxolitinib—Malnutrition—Topotecan—cervical cancer	0.00217	0.033	CcSEcCtD
Ruxolitinib—DAPK3—female reproductive system—cervical cancer	0.00217	0.00481	CbGeAlD
Ruxolitinib—LRRK2—endometrium—cervical cancer	0.00217	0.00481	CbGeAlD
Ruxolitinib—CLK2—female reproductive system—cervical cancer	0.00215	0.00477	CbGeAlD
Ruxolitinib—CAMK1D—female gonad—cervical cancer	0.00215	0.00477	CbGeAlD
Ruxolitinib—PHKG2—female gonad—cervical cancer	0.00214	0.00474	CbGeAlD
Ruxolitinib—CAMK1D—vagina—cervical cancer	0.00213	0.00474	CbGeAlD
Ruxolitinib—TYK2—uterine cervix—cervical cancer	0.00213	0.00474	CbGeAlD
Ruxolitinib—MKNK2—epithelium—cervical cancer	0.00212	0.00471	CbGeAlD
Ruxolitinib—IRAK1—uterine cervix—cervical cancer	0.00211	0.00467	CbGeAlD
Ruxolitinib—MKNK2—uterine cervix—cervical cancer	0.00211	0.00467	CbGeAlD
Ruxolitinib—DAPK2—female gonad—cervical cancer	0.0021	0.00466	CbGeAlD
Ruxolitinib—LRRK2—mammalian vulva—cervical cancer	0.0021	0.00465	CbGeAlD
Ruxolitinib—DAPK2—vagina—cervical cancer	0.00209	0.00463	CbGeAlD
Ruxolitinib—ROCK1—female reproductive system—cervical cancer	0.00208	0.00462	CbGeAlD
Ruxolitinib—RET—epithelium—cervical cancer	0.00207	0.0046	CbGeAlD
Ruxolitinib—MAP3K7—decidua—cervical cancer	0.00207	0.0046	CbGeAlD
Ruxolitinib—STK16—female gonad—cervical cancer	0.00207	0.00458	CbGeAlD
Ruxolitinib—HIPK2—female gonad—cervical cancer	0.00205	0.00456	CbGeAlD
Ruxolitinib—STK16—vagina—cervical cancer	0.00205	0.00456	CbGeAlD
Ruxolitinib—TYK2—decidua—cervical cancer	0.00203	0.00451	CbGeAlD
Ruxolitinib—DYRK1A—female reproductive system—cervical cancer	0.00203	0.00451	CbGeAlD
Ruxolitinib—BMPR2—female reproductive system—cervical cancer	0.00202	0.00449	CbGeAlD
Ruxolitinib—CAMK2G—uterus—cervical cancer	0.00201	0.00447	CbGeAlD
Ruxolitinib—IRAK1—decidua—cervical cancer	0.00201	0.00445	CbGeAlD
Ruxolitinib—MKNK2—decidua—cervical cancer	0.00201	0.00445	CbGeAlD
Ruxolitinib—Anaemia—Topotecan—cervical cancer	0.00201	0.0305	CcSEcCtD
Ruxolitinib—TYK2—renal system—cervical cancer	0.002	0.00443	CbGeAlD
Ruxolitinib—DAPK3—female gonad—cervical cancer	0.00197	0.00438	CbGeAlD
Ruxolitinib—MKNK2—renal system—cervical cancer	0.00197	0.00437	CbGeAlD
Ruxolitinib—MAP3K7—endometrium—cervical cancer	0.00197	0.00436	CbGeAlD
Ruxolitinib—DAPK3—vagina—cervical cancer	0.00196	0.00435	CbGeAlD
Ruxolitinib—JAK2—epithelium—cervical cancer	0.00196	0.00435	CbGeAlD
Ruxolitinib—RET—decidua—cervical cancer	0.00196	0.00434	CbGeAlD
Ruxolitinib—CLK2—female gonad—cervical cancer	0.00196	0.00434	CbGeAlD
Ruxolitinib—CLK2—vagina—cervical cancer	0.00194	0.00431	CbGeAlD
Ruxolitinib—JAK2—uterine cervix—cervical cancer	0.00194	0.00431	CbGeAlD
Ruxolitinib—TYK2—endometrium—cervical cancer	0.00193	0.00428	CbGeAlD
Ruxolitinib—RET—renal system—cervical cancer	0.00192	0.00426	CbGeAlD
Ruxolitinib—MKNK2—endometrium—cervical cancer	0.00191	0.00423	CbGeAlD
Ruxolitinib—MAP3K7—mammalian vulva—cervical cancer	0.0019	0.00422	CbGeAlD
Ruxolitinib—ROCK1—female gonad—cervical cancer	0.0019	0.0042	CbGeAlD
Ruxolitinib—MAP3K3—uterine cervix—cervical cancer	0.00187	0.00415	CbGeAlD
Ruxolitinib—TYK2—mammalian vulva—cervical cancer	0.00187	0.00414	CbGeAlD
Ruxolitinib—JAK2—decidua—cervical cancer	0.00185	0.00411	CbGeAlD
Ruxolitinib—DYRK1A—female gonad—cervical cancer	0.00185	0.0041	CbGeAlD
Ruxolitinib—PLK3—lymph node—cervical cancer	0.00184	0.00409	CbGeAlD
Ruxolitinib—IRAK1—mammalian vulva—cervical cancer	0.00184	0.00409	CbGeAlD
Ruxolitinib—MKNK2—mammalian vulva—cervical cancer	0.00184	0.00409	CbGeAlD
Ruxolitinib—BMPR2—female gonad—cervical cancer	0.00184	0.00408	CbGeAlD
Ruxolitinib—Unspecified disorder of skin and subcutaneous tissue—Topotecan—cervical cancer	0.00184	0.0279	CcSEcCtD
Ruxolitinib—BMPR2—vagina—cervical cancer	0.00183	0.00406	CbGeAlD
Ruxolitinib—MAP3K2—uterus—cervical cancer	0.00183	0.00406	CbGeAlD
Ruxolitinib—JAK2—renal system—cervical cancer	0.00182	0.00403	CbGeAlD
Ruxolitinib—MAP3K7—uterus—cervical cancer	0.00181	0.00402	CbGeAlD
Ruxolitinib—BMP2K—female reproductive system—cervical cancer	0.00181	0.00402	CbGeAlD
Ruxolitinib—CAMK2G—female reproductive system—cervical cancer	0.00181	0.00402	CbGeAlD
Ruxolitinib—LRRK2—female reproductive system—cervical cancer	0.00179	0.00398	CbGeAlD
Ruxolitinib—MAP3K3—decidua—cervical cancer	0.00178	0.00396	CbGeAlD
Ruxolitinib—LTK—lymph node—cervical cancer	0.00178	0.00395	CbGeAlD
Ruxolitinib—TYK2—uterus—cervical cancer	0.00178	0.00395	CbGeAlD
Ruxolitinib—Infection—Topotecan—cervical cancer	0.00176	0.0268	CcSEcCtD
Ruxolitinib—NUAK2—female gonad—cervical cancer	0.00176	0.0039	CbGeAlD
Ruxolitinib—JAK2—endometrium—cervical cancer	0.00176	0.0039	CbGeAlD
Ruxolitinib—MKNK2—uterus—cervical cancer	0.00176	0.0039	CbGeAlD
Ruxolitinib—NUAK2—vagina—cervical cancer	0.00175	0.00388	CbGeAlD
Ruxolitinib—Nervous system disorder—Topotecan—cervical cancer	0.00174	0.0264	CcSEcCtD
Ruxolitinib—Thrombocytopenia—Topotecan—cervical cancer	0.00173	0.0264	CcSEcCtD
Ruxolitinib—CAMK1—lymph node—cervical cancer	0.00172	0.00383	CbGeAlD
Ruxolitinib—Skin disorder—Topotecan—cervical cancer	0.00172	0.0262	CcSEcCtD
Ruxolitinib—TAOK3—uterine cervix—cervical cancer	0.00171	0.00379	CbGeAlD
Ruxolitinib—JAK2—mammalian vulva—cervical cancer	0.0017	0.00377	CbGeAlD
Ruxolitinib—MAP3K3—endometrium—cervical cancer	0.00169	0.00376	CbGeAlD
Ruxolitinib—MARK2—lymph node—cervical cancer	0.00167	0.00372	CbGeAlD
Ruxolitinib—CAMK2G—female gonad—cervical cancer	0.00165	0.00366	CbGeAlD
Ruxolitinib—BMP2K—female gonad—cervical cancer	0.00165	0.00366	CbGeAlD
Ruxolitinib—MAP3K2—female reproductive system—cervical cancer	0.00164	0.00365	CbGeAlD
Ruxolitinib—MAP3K3—mammalian vulva—cervical cancer	0.00164	0.00363	CbGeAlD
Ruxolitinib—CAMK2G—vagina—cervical cancer	0.00164	0.00363	CbGeAlD
Ruxolitinib—BMP2K—vagina—cervical cancer	0.00164	0.00363	CbGeAlD
Ruxolitinib—LRRK2—female gonad—cervical cancer	0.00163	0.00362	CbGeAlD
Ruxolitinib—TAOK3—decidua—cervical cancer	0.00163	0.00361	CbGeAlD
Ruxolitinib—LRRK2—vagina—cervical cancer	0.00162	0.0036	CbGeAlD
Ruxolitinib—TYK2—female reproductive system—cervical cancer	0.0016	0.00355	CbGeAlD
Ruxolitinib—TAOK3—renal system—cervical cancer	0.0016	0.00354	CbGeAlD
Ruxolitinib—IRAK1—female reproductive system—cervical cancer	0.00158	0.0035	CbGeAlD
Ruxolitinib—MKNK2—female reproductive system—cervical cancer	0.00158	0.0035	CbGeAlD
Ruxolitinib—TAOK2—lymph node—cervical cancer	0.00155	0.00344	CbGeAlD
Ruxolitinib—TAOK3—endometrium—cervical cancer	0.00154	0.00342	CbGeAlD
Ruxolitinib—Gastrointestinal disorder—Topotecan—cervical cancer	0.00153	0.0233	CcSEcCtD
Ruxolitinib—Fatigue—Topotecan—cervical cancer	0.00153	0.0233	CcSEcCtD
Ruxolitinib—MAP3K2—female gonad—cervical cancer	0.0015	0.00332	CbGeAlD
Ruxolitinib—TAOK3—mammalian vulva—cervical cancer	0.00149	0.00331	CbGeAlD
Ruxolitinib—MAP3K7—female gonad—cervical cancer	0.00148	0.00329	CbGeAlD
Ruxolitinib—MAP3K7—vagina—cervical cancer	0.00147	0.00327	CbGeAlD
Ruxolitinib—TYK2—female gonad—cervical cancer	0.00146	0.00323	CbGeAlD
Ruxolitinib—JAK2—female reproductive system—cervical cancer	0.00145	0.00323	CbGeAlD
Ruxolitinib—TYK2—vagina—cervical cancer	0.00145	0.00321	CbGeAlD
Ruxolitinib—MKNK2—female gonad—cervical cancer	0.00144	0.00319	CbGeAlD
Ruxolitinib—IRAK1—female gonad—cervical cancer	0.00144	0.00319	CbGeAlD
Ruxolitinib—MKNK2—vagina—cervical cancer	0.00143	0.00317	CbGeAlD
Ruxolitinib—JAK3—lymph node—cervical cancer	0.00142	0.00316	CbGeAlD
Ruxolitinib—TAOK3—uterus—cervical cancer	0.00142	0.00316	CbGeAlD
Ruxolitinib—JAK1—lymph node—cervical cancer	0.00141	0.00314	CbGeAlD
Ruxolitinib—DCLK1—lymph node—cervical cancer	0.00141	0.00314	CbGeAlD
Ruxolitinib—PLK4—lymph node—cervical cancer	0.00141	0.00312	CbGeAlD
Ruxolitinib—MAP3K3—female reproductive system—cervical cancer	0.0014	0.00311	CbGeAlD
Ruxolitinib—Body temperature increased—Topotecan—cervical cancer	0.0014	0.0213	CcSEcCtD
Ruxolitinib—CAMK1D—lymph node—cervical cancer	0.00138	0.00306	CbGeAlD
Ruxolitinib—PHKG2—lymph node—cervical cancer	0.00137	0.00305	CbGeAlD
Ruxolitinib—DAPK2—lymph node—cervical cancer	0.00135	0.00299	CbGeAlD
Ruxolitinib—STK16—lymph node—cervical cancer	0.00133	0.00295	CbGeAlD
Ruxolitinib—JAK2—female gonad—cervical cancer	0.00132	0.00294	CbGeAlD
Ruxolitinib—HIPK2—lymph node—cervical cancer	0.00132	0.00293	CbGeAlD
Ruxolitinib—JAK2—vagina—cervical cancer	0.00132	0.00292	CbGeAlD
Ruxolitinib—TAOK3—female reproductive system—cervical cancer	0.00128	0.00284	CbGeAlD
Ruxolitinib—MAP3K3—female gonad—cervical cancer	0.00128	0.00283	CbGeAlD
Ruxolitinib—Asthenia—Topotecan—cervical cancer	0.00127	0.0194	CcSEcCtD
Ruxolitinib—DAPK3—lymph node—cervical cancer	0.00127	0.00282	CbGeAlD
Ruxolitinib—MAP3K3—vagina—cervical cancer	0.00127	0.00281	CbGeAlD
Ruxolitinib—CLK2—lymph node—cervical cancer	0.00126	0.00279	CbGeAlD
Ruxolitinib—Pruritus—Topotecan—cervical cancer	0.00125	0.0191	CcSEcCtD
Ruxolitinib—DYRK1A—lymph node—cervical cancer	0.00119	0.00264	CbGeAlD
Ruxolitinib—BMPR2—lymph node—cervical cancer	0.00118	0.00263	CbGeAlD
Ruxolitinib—Dizziness—Topotecan—cervical cancer	0.00117	0.0178	CcSEcCtD
Ruxolitinib—TAOK3—female gonad—cervical cancer	0.00116	0.00258	CbGeAlD
Ruxolitinib—TAOK3—vagina—cervical cancer	0.00116	0.00257	CbGeAlD
Ruxolitinib—NUAK2—lymph node—cervical cancer	0.00113	0.00251	CbGeAlD
Ruxolitinib—Headache—Topotecan—cervical cancer	0.00111	0.0169	CcSEcCtD
Ruxolitinib—CAMK2G—lymph node—cervical cancer	0.00106	0.00235	CbGeAlD
Ruxolitinib—BMP2K—lymph node—cervical cancer	0.00106	0.00235	CbGeAlD
Ruxolitinib—LRRK2—lymph node—cervical cancer	0.00105	0.00233	CbGeAlD
Ruxolitinib—MAP3K2—lymph node—cervical cancer	0.000962	0.00213	CbGeAlD
Ruxolitinib—MAP3K7—lymph node—cervical cancer	0.000953	0.00211	CbGeAlD
Ruxolitinib—TYK2—lymph node—cervical cancer	0.000935	0.00208	CbGeAlD
Ruxolitinib—IRAK1—lymph node—cervical cancer	0.000923	0.00205	CbGeAlD
Ruxolitinib—MKNK2—lymph node—cervical cancer	0.000923	0.00205	CbGeAlD
Ruxolitinib—RET—lymph node—cervical cancer	0.0009	0.002	CbGeAlD
Ruxolitinib—JAK2—lymph node—cervical cancer	0.000851	0.00189	CbGeAlD
Ruxolitinib—MAP3K3—lymph node—cervical cancer	0.00082	0.00182	CbGeAlD
Ruxolitinib—TAOK3—lymph node—cervical cancer	0.000748	0.00166	CbGeAlD
Ruxolitinib—CYP3A4—renal system—cervical cancer	0.000485	0.00108	CbGeAlD
Ruxolitinib—CYP3A4—female reproductive system—cervical cancer	0.000388	0.000862	CbGeAlD
Ruxolitinib—JAK2—Developmental Biology—NOTCH1—cervical cancer	5.98e-05	0.000128	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MTHFR—cervical cancer	5.91e-05	0.000127	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—CTNNB1—cervical cancer	5.89e-05	0.000126	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—TERT—cervical cancer	5.89e-05	0.000126	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—WNT5A—cervical cancer	5.86e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—FGFR3—cervical cancer	5.85e-05	0.000125	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—HLA-DQB1—cervical cancer	5.83e-05	0.000125	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CASP8—cervical cancer	5.82e-05	0.000125	CbGpPWpGaD
Ruxolitinib—TYK2—Axon guidance—EGFR—cervical cancer	5.82e-05	0.000125	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CASP3—cervical cancer	5.74e-05	0.000123	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOTCH2—cervical cancer	5.74e-05	0.000123	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TERT—cervical cancer	5.68e-05	0.000122	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—MTOR—cervical cancer	5.67e-05	0.000122	CbGpPWpGaD
Ruxolitinib—PHKG2—Disease—EGFR—cervical cancer	5.67e-05	0.000121	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CD4—cervical cancer	5.66e-05	0.000121	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—HLA-DQB1—cervical cancer	5.66e-05	0.000121	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—MTOR—cervical cancer	5.65e-05	0.000121	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOTCH2—cervical cancer	5.65e-05	0.000121	CbGpPWpGaD
Ruxolitinib—JAK1—Developmental Biology—EGFR—cervical cancer	5.62e-05	0.000121	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—FGFR3—cervical cancer	5.62e-05	0.00012	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—CTNNB1—cervical cancer	5.54e-05	0.000119	CbGpPWpGaD
Ruxolitinib—ROCK1—Developmental Biology—EGFR—cervical cancer	5.53e-05	0.000119	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DPB1—cervical cancer	5.49e-05	0.000118	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—HLA-DQB1—cervical cancer	5.49e-05	0.000118	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—HES1—cervical cancer	5.47e-05	0.000117	CbGpPWpGaD
Ruxolitinib—JAK2—Cytokine Signaling in Immune system—STAT3—cervical cancer	5.45e-05	0.000117	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD8A—cervical cancer	5.44e-05	0.000117	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—FGFR3—cervical cancer	5.4e-05	0.000116	CbGpPWpGaD
Ruxolitinib—JAK3—Hemostasis—TP53—cervical cancer	5.38e-05	0.000115	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—MTOR—cervical cancer	5.38e-05	0.000115	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CD4—cervical cancer	5.37e-05	0.000115	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—STAT3—cervical cancer	5.36e-05	0.000115	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—AKAP13—cervical cancer	5.3e-05	0.000114	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD8A—cervical cancer	5.28e-05	0.000113	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—CTNNB1—cervical cancer	5.24e-05	0.000112	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—MTOR—cervical cancer	5.24e-05	0.000112	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CD4—cervical cancer	5.23e-05	0.000112	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—MTOR—cervical cancer	5.22e-05	0.000112	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—FGFR3—cervical cancer	5.21e-05	0.000112	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CD4—cervical cancer	5.21e-05	0.000112	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—MTOR—cervical cancer	5.2e-05	0.000111	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CASP3—cervical cancer	5.19e-05	0.000111	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CD4—cervical cancer	5.19e-05	0.000111	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—STAT3—cervical cancer	5.13e-05	0.00011	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD8A—cervical cancer	5.12e-05	0.00011	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—MTOR—cervical cancer	5.07e-05	0.000109	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—NOTCH1—cervical cancer	5.07e-05	0.000109	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CD4—cervical cancer	5.06e-05	0.000109	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—MTOR—cervical cancer	5.06e-05	0.000108	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CD4—cervical cancer	5.05e-05	0.000108	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—CTNNB1—cervical cancer	5.03e-05	0.000108	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—CTNNB1—cervical cancer	5.01e-05	0.000107	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CASP8—cervical cancer	5.01e-05	0.000107	CbGpPWpGaD
Ruxolitinib—JAK1—Innate Immune System—EGFR—cervical cancer	4.97e-05	0.000106	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—HES1—cervical cancer	4.96e-05	0.000106	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—NOTCH1—cervical cancer	4.89e-05	0.000105	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by NGF—EGFR—cervical cancer	4.87e-05	0.000104	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—MTOR—cervical cancer	4.86e-05	0.000104	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—CD4—cervical cancer	4.85e-05	0.000104	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—STAT3—cervical cancer	4.83e-05	0.000103	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CASP8—cervical cancer	4.81e-05	0.000103	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TERT—cervical cancer	4.79e-05	0.000103	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—MTOR—cervical cancer	4.79e-05	0.000103	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CD4—cervical cancer	4.78e-05	0.000102	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—CTNNB1—cervical cancer	4.77e-05	0.000102	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—HES1—cervical cancer	4.71e-05	0.000101	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—EGFR—cervical cancer	4.67e-05	0.0001	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—CTNNB1—cervical cancer	4.64e-05	9.95e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Hemostasis—TP53—cervical cancer	4.63e-05	9.93e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—HES1—cervical cancer	4.63e-05	9.92e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—CTNNB1—cervical cancer	4.63e-05	9.92e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—CTNNB1—cervical cancer	4.61e-05	9.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—WNT5A—cervical cancer	4.58e-05	9.81e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—STAT3—cervical cancer	4.57e-05	9.79e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—CTNNB1—cervical cancer	4.5e-05	9.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—CTNNB1—cervical cancer	4.49e-05	9.62e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—FGFR3—cervical cancer	4.45e-05	9.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Axon guidance—EGFR—cervical cancer	4.41e-05	9.45e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—FGFR3—cervical cancer	4.4e-05	9.43e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—EGFR—cervical cancer	4.39e-05	9.4e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—STAT3—cervical cancer	4.38e-05	9.39e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH2—cervical cancer	4.36e-05	9.35e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—STAT3—cervical cancer	4.36e-05	9.35e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling by GPCR—EGFR—cervical cancer	4.36e-05	9.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTHFR—cervical cancer	4.36e-05	9.34e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—TERT—cervical cancer	4.35e-05	9.32e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—FGFR3—cervical cancer	4.32e-05	9.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—HLA-DQB1—cervical cancer	4.29e-05	9.19e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—CTNNB1—cervical cancer	4.24e-05	9.09e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH2—cervical cancer	4.24e-05	9.08e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—FGFR3—cervical cancer	4.19e-05	8.98e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Developmental Biology—EGFR—cervical cancer	4.15e-05	8.9e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—NOTCH1—cervical cancer	4.13e-05	8.85e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TERT—cervical cancer	4.12e-05	8.84e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—MTOR—cervical cancer	4.12e-05	8.83e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CD4—cervical cancer	4.11e-05	8.81e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH2—cervical cancer	4.11e-05	8.81e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TERT—cervical cancer	4.06e-05	8.69e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—STAT3—cervical cancer	4.05e-05	8.67e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—STAT3—cervical cancer	4.01e-05	8.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD8A—cervical cancer	4e-05	8.58e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—FGFR3—cervical cancer	3.99e-05	8.55e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Immune System—EGFR—cervical cancer	3.98e-05	8.54e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—CTNNB1—cervical cancer	3.97e-05	8.51e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—EGFR—cervical cancer	3.97e-05	8.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—MTOR—cervical cancer	3.96e-05	8.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CD4—cervical cancer	3.95e-05	8.46e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—STAT3—cervical cancer	3.92e-05	8.4e-05	CbGpPWpGaD
Ruxolitinib—PRKG2—Signaling Pathways—TP53—cervical cancer	3.92e-05	8.4e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CASP8—cervical cancer	3.81e-05	8.16e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—MTOR—cervical cancer	3.8e-05	8.15e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CD4—cervical cancer	3.79e-05	8.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—FGFR3—cervical cancer	3.78e-05	8.11e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Innate Immune System—EGFR—cervical cancer	3.78e-05	8.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—HES1—cervical cancer	3.76e-05	8.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—NOTCH1—cervical cancer	3.75e-05	8.03e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—FGFR3—cervical cancer	3.72e-05	7.98e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—STAT3—cervical cancer	3.7e-05	7.93e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CASP8—cervical cancer	3.69e-05	7.92e-05	CbGpPWpGaD
Ruxolitinib—GRK1—Signaling Pathways—TP53—cervical cancer	3.68e-05	7.89e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling by GPCR—EGFR—cervical cancer	3.68e-05	7.89e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Disease—EGFR—cervical cancer	3.68e-05	7.88e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—MTOR—cervical cancer	3.67e-05	7.86e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Innate Immune System—EGFR—cervical cancer	3.67e-05	7.86e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—CTNNB1—cervical cancer	3.65e-05	7.82e-05	CbGpPWpGaD
Ruxolitinib—CAMK2G—Immune System—EGFR—cervical cancer	3.65e-05	7.82e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CASP8—cervical cancer	3.58e-05	7.68e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—HES1—cervical cancer	3.58e-05	7.67e-05	CbGpPWpGaD
Ruxolitinib—MAP3K3—Immune System—EGFR—cervical cancer	3.56e-05	7.64e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Innate Immune System—EGFR—cervical cancer	3.56e-05	7.62e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—NOTCH1—cervical cancer	3.55e-05	7.61e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—CTNNB1—cervical cancer	3.51e-05	7.52e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—NOTCH1—cervical cancer	3.49e-05	7.49e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—HES1—cervical cancer	3.47e-05	7.45e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—STAT3—cervical cancer	3.46e-05	7.42e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Adaptive Immune System—EGFR—cervical cancer	3.41e-05	7.32e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CASP3—cervical cancer	3.37e-05	7.23e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—CTNNB1—cervical cancer	3.37e-05	7.22e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—HES1—cervical cancer	3.37e-05	7.22e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Immune System—EGFR—cervical cancer	3.36e-05	7.21e-05	CbGpPWpGaD
Ruxolitinib—BMPR2—Signaling Pathways—TP53—cervical cancer	3.33e-05	7.14e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTHFR—cervical cancer	3.3e-05	7.08e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—TERT—cervical cancer	3.29e-05	7.06e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—FGFR3—cervical cancer	3.27e-05	7.02e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—CTNNB1—cervical cancer	3.25e-05	6.97e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH2—cervical cancer	3.21e-05	6.88e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—STAT3—cervical cancer	3.18e-05	6.82e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling by GPCR—EGFR—cervical cancer	3.17e-05	6.78e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Developmental Biology—EGFR—cervical cancer	3.15e-05	6.74e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TERT—cervical cancer	3.14e-05	6.72e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—MTOR—cervical cancer	3.13e-05	6.71e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CD4—cervical cancer	3.13e-05	6.7e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling by GPCR—EGFR—cervical cancer	3.11e-05	6.67e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—MTOR—cervical cancer	3.09e-05	6.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TERT—cervical cancer	3.04e-05	6.52e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—MTOR—cervical cancer	3.04e-05	6.51e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CD4—cervical cancer	3.03e-05	6.5e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—FGFR3—cervical cancer	3.02e-05	6.48e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TERT—cervical cancer	2.95e-05	6.33e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—MTOR—cervical cancer	2.95e-05	6.32e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CD4—cervical cancer	2.94e-05	6.31e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—STAT3—cervical cancer	2.94e-05	6.3e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Immune System—EGFR—cervical cancer	2.89e-05	6.2e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—FGFR3—cervical cancer	2.88e-05	6.17e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CASP3—cervical cancer	2.85e-05	6.1e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—NOTCH1—cervical cancer	2.84e-05	6.08e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—STAT3—cervical cancer	2.83e-05	6.07e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—MTOR—cervical cancer	2.81e-05	6.02e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CD4—cervical cancer	2.8e-05	6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CASP8—cervical cancer	2.8e-05	6e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—FGFR3—cervical cancer	2.79e-05	5.99e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Innate Immune System—EGFR—cervical cancer	2.78e-05	5.95e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—CTNNB1—cervical cancer	2.78e-05	5.95e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—CTNNB1—cervical cancer	2.74e-05	5.88e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—FGFR3—cervical cancer	2.71e-05	5.81e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—NOTCH1—cervical cancer	2.7e-05	5.79e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—CTNNB1—cervical cancer	2.7e-05	5.78e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Disease—EGFR—cervical cancer	2.67e-05	5.72e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—MTOR—cervical cancer	2.66e-05	5.71e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—HES1—cervical cancer	2.63e-05	5.64e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—NOTCH1—cervical cancer	2.62e-05	5.62e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—MTOR—cervical cancer	2.62e-05	5.61e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—CTNNB1—cervical cancer	2.61e-05	5.6e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Hemostasis—TP53—cervical cancer	2.59e-05	5.55e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—EGFR—cervical cancer	2.58e-05	5.52e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—NOTCH1—cervical cancer	2.54e-05	5.45e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—CTNNB1—cervical cancer	2.49e-05	5.33e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CASP3—cervical cancer	2.45e-05	5.25e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—STAT3—cervical cancer	2.42e-05	5.19e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CASP3—cervical cancer	2.41e-05	5.16e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—STAT3—cervical cancer	2.39e-05	5.13e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—CTNNB1—cervical cancer	2.36e-05	5.06e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—STAT3—cervical cancer	2.35e-05	5.03e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling by GPCR—EGFR—cervical cancer	2.34e-05	5.01e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—CTNNB1—cervical cancer	2.32e-05	4.98e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TERT—cervical cancer	2.31e-05	4.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—MTOR—cervical cancer	2.3e-05	4.94e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CD4—cervical cancer	2.3e-05	4.93e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—STAT3—cervical cancer	2.28e-05	4.88e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Immune System—EGFR—cervical cancer	2.2e-05	4.71e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—EGFR—cervical cancer	2.17e-05	4.66e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—STAT3—cervical cancer	2.17e-05	4.65e-05	CbGpPWpGaD
Ruxolitinib—PRKCE—Signaling Pathways—TP53—cervical cancer	2.16e-05	4.63e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Immune System—EGFR—cervical cancer	2.14e-05	4.58e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—MTOR—cervical cancer	2.13e-05	4.56e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CD4—cervical cancer	2.12e-05	4.55e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—FGFR3—cervical cancer	2.12e-05	4.54e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Immune System—EGFR—cervical cancer	2.07e-05	4.44e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—STAT3—cervical cancer	2.06e-05	4.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—CTNNB1—cervical cancer	2.04e-05	4.38e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—MTOR—cervical cancer	2.02e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—STAT3—cervical cancer	2.02e-05	4.34e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—NOTCH1—cervical cancer	1.99e-05	4.26e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Disease—EGFR—cervical cancer	1.97e-05	4.22e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—MTOR—cervical cancer	1.97e-05	4.21e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—CA9—cervical cancer	1.93e-05	4.13e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—MTOR—cervical cancer	1.91e-05	4.09e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—CTNNB1—cervical cancer	1.89e-05	4.04e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—EGFR—cervical cancer	1.87e-05	4.01e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CASP3—cervical cancer	1.86e-05	3.99e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—EGFR—cervical cancer	1.84e-05	3.94e-05	CbGpPWpGaD
Ruxolitinib—JAK3—Signaling Pathways—TP53—cervical cancer	1.83e-05	3.91e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CASP3—cervical cancer	1.81e-05	3.87e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—CTNNB1—cervical cancer	1.79e-05	3.85e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—STAT3—cervical cancer	1.78e-05	3.82e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling by GPCR—EGFR—cervical cancer	1.77e-05	3.8e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CASP3—cervical cancer	1.75e-05	3.76e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—CTNNB1—cervical cancer	1.74e-05	3.73e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—CTNNB1—cervical cancer	1.69e-05	3.62e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—STAT3—cervical cancer	1.64e-05	3.52e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Immune System—EGFR—cervical cancer	1.62e-05	3.47e-05	CbGpPWpGaD
Ruxolitinib—JAK1—Signaling Pathways—TP53—cervical cancer	1.57e-05	3.36e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—STAT3—cervical cancer	1.56e-05	3.35e-05	CbGpPWpGaD
Ruxolitinib—ROCK1—Signaling Pathways—TP53—cervical cancer	1.54e-05	3.31e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—STAT3—cervical cancer	1.52e-05	3.26e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Disease—EGFR—cervical cancer	1.49e-05	3.2e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—MTOR—cervical cancer	1.49e-05	3.19e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—STAT3—cervical cancer	1.47e-05	3.16e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—EGFR—cervical cancer	1.42e-05	3.05e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—EGFR—cervical cancer	1.38e-05	2.96e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CASP3—cervical cancer	1.37e-05	2.94e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—EGFR—cervical cancer	1.34e-05	2.87e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—CTNNB1—cervical cancer	1.32e-05	2.83e-05	CbGpPWpGaD
Ruxolitinib—IRAK1—Signaling Pathways—TP53—cervical cancer	1.19e-05	2.56e-05	CbGpPWpGaD
Ruxolitinib—TYK2—Signaling Pathways—TP53—cervical cancer	1.16e-05	2.48e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—STAT3—cervical cancer	1.15e-05	2.47e-05	CbGpPWpGaD
Ruxolitinib—MAP3K7—Signaling Pathways—TP53—cervical cancer	1.12e-05	2.41e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—EGFR—cervical cancer	1.05e-05	2.24e-05	CbGpPWpGaD
Ruxolitinib—JAK2—Signaling Pathways—TP53—cervical cancer	8.78e-06	1.88e-05	CbGpPWpGaD
Ruxolitinib—CYP3A4—Metabolism—MTHFR—cervical cancer	7.82e-06	1.68e-05	CbGpPWpGaD
